Your search returned 5 results.

Results
	1.	Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report. MedStar authors: Sackstein, Paul Zaemes, Jacob PMID: 34330765 Year: 2021 Citation: Journal for Immunotherapy of Cancer. 9(7), 2021 07. Department: Internal Medicine Residency MedStar Georgetown University Hospital Medline publication type: Journal Article Form of publication: Journal Article All authors: Kim C, Sackstein P, Zaemes J DOI: https://dx.doi.org/10.1136/jitc-2021-002855 Add to cart (remove)
	2.	Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. MedStar authors: Weinstein, Arthur PMID: 24187095 Year: 2014 Citation: Journal of Rheumatology. 41(2):300-9, 2014 Feb. Institution: MedStar Washington Hospital Center Department: Medicine/Rheumatology Medline publication type: Clinical Trial, Phase II Journal Article Randomized Controlled Trial Form of publication: Journal Article All authors: Chatham WW, Freimuth WW, Furie RA, Ginzler EM, LBSL02/99 Study Group, McCune WJ, McKay JD, Merrill JT, Petri MA, Stohl W, Wallace DJ, Weinstein A, Zhong ZJ DOI: http://dx.doi.org/10.3899/jrheum.121368 Add to cart (remove)
	3.	Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. MedStar authors: Priebat, Dennis A PMID: 28988646 Year: 2017 Citation: Lancet Oncology. 18(11):1493-1501, 2017 Nov Institution: Washington Cancer Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Attia S, Baker LH, Bolejack V, Burgess M, Butterfield LH, Crowley J, D'Angelo S, Davis LE, Hu J, Lazar AJ, Maki RG, Movva S, Okuno SH, Patel S, Priebat DA, Reed DR, Reinke D, Riedel RF, Rodriguez-Canales J, Salazar R, Schuetze SM, Tawbi HA, Van Tine BA, Wistuba II DOI: https://dx.doi.org/10.1016/S1470-2045(17)30624-1 Add to cart (remove)
	4.	Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. MedStar authors: Rao, Suman PMID: 29129441 Year: 2017 Citation: Lancet Oncology. 18(12):1600-1609, 2017 Dec Institution: MedStar Franklin Square Hospital Medline publication type: Journal Article Form of publication: Journal Article All authors: Brahmer JR, Csoszi T, Cuffe S, Deitz AC, Fulop A, Gottfried M, Hotta K, Hui R, Lubiniecki GM, O'Brien M, Peled N, Rangwala R, Rao S, Reck M, Robinson AG, Rodriguez-Abreu D, Tafreshi A, Zhang J DOI: https://dx.doi.org/10.1016/S1470-2045(17)30690-3 Add to cart (remove)
	5.	Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. MedStar authors: Rao, Suman PMID: 30620668 Year: 2019 Citation: Journal of Clinical Oncology. 37(7):537-546, 2019 03 01. Institution: Medstar Franklin Square Medical Center Medline publication type: Journal Article Form of publication: Journal Article All authors: Brahmer JR, Csoszi T, Cuffe S, Fulop A, Gottfried M, Hotta K, Hui R, O'Brien M, Peled N, Pietanza MC, Rao S, Reck M, Riccio A, Robinson AG, Rodriguez-Abreu D, Tafreshi A, Vandormael K, Yang J DOI: https://dx.doi.org/10.1200/JCO.18.00149 Add to cart (remove)

Powered by Koha